Q-omics provides the consensus-scored RAB28 profile across patient tissues and cancer cell-line models. RAB28 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RAB28 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, RAB28 RNA expression shows 19,596 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, LIHC, and ACC as cancer lineages where RAB28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB28 survival associations across molecular data types. RAB28 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB28 RNA expression–survival associations across cancer types. High RAB28 expression shows unfavorable associations in KICH, ACC and KIRP, but favorable associations in UCS, SKCM and COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for RAB28 RNA expression.
This table summarizes RAB28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB28 shows lower tumor expression in THCA, LUAD, UCEC and KIRC and higher tumor expression in LIHC and HNSC. The LIHC box plot shows higher RAB28 RNA expression in tumor versus normal tissue (log2 FC = +0.833, t-test p < 0.001).
This table shows molecular features associated with RAB28 in patient tissues and cancer cell lines. In patient samples, RAB28 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
